On June 8, 2020, Surmodics, Inc. (the “Company”) issued a press release announcing that it has received CE Mark Certification in the European Union for its SurVeil™ drug-coated balloon. In the press release, the Company also disclosed the milestone payment that that it will receive related to obtaining the CE Mark. A copy of a press release announcing the foregoing is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1	Press release dated June 8, 2020

SURMODICS INC Exhibit
EX-99.1 2 a52231228ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Surmodics Receives CE Mark for its SurVeil™ Drug Coated Balloon Next generation device adds new technology to how physicians approach treatment of PAD EDEN PRAIRIE,…
To view the full exhibit click here

About Surmodics, Inc. (NASDAQ:SRDX)

Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.